Generic Name and Formulations:
Fluticasone propionate 50mcg/spray; aqueous nasal spray.
Various generic manufacturers
Indications for Fluticasone:
Perennial nonallergic rhinitis.
Initially 2 sprays in each nostril once daily or 1 spray in each nostril twice daily (AM and PM). Maintenance: may reduce to 1 spray in each nostril daily. Max total daily doses: 2 sprays in each nostril (200mcg/day).
<4yrs: not established. ≥4yrs: initially 1 spray in each nostril once daily; may increase to 2 sprays in each nostril once daily. Maintenance: 1 spray in each nostril once daily. Max total daily doses: 2 sprays in each nostril (200mcg/day).
Maintain regular regimen. Respiratory tract tuberculosis. Infections (eg, ocular herpes simplex). If exposed to measles or chickenpox, consider anti-infective prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with topical corticosteroids may exacerbate symptoms of adrenal insufficiency (eg, depression). Monitor for growth suppression in children. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually), and candida infection or other nasal mucosal changes. Avoid eyes. Pregnancy (Cat.C). Nursing mothers.
Avoid ritonavir. Caution with potent CYP3A4 inhibitors (eg, ketoconazole).
Headache, pharyngitis, epistaxis, nasal burning, asthma symptoms, GI upset, cough, reduced growth velocity in children.
Formerly known under the brand name Flonase.
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Effect of Infant Feeding Practices and Gut Microbiota on Overweight in First Year
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Cleared Blood Glucose Monitor Systems Not Always Accurate
- CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
- Vascular Mortality Declining in Adults With Diabetes in the United States